Miller Global Investments LLC Invests $875,000 in Pfizer Inc. $PFE

Miller Global Investments LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 35,145 shares of the biopharmaceutical company’s stock, valued at approximately $875,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp grew its position in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the last quarter. Norges Bank purchased a new position in shares of Pfizer during the second quarter valued at approximately $2,270,157,000. Northern Trust Corp increased its stake in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after acquiring an additional 897,786 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 2.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 TALAPRO‑3 topline: the TALZENNA (talazoparib) + XTANDI (enzalutamide) combo met the study’s primary endpoint with a significant improvement in radiographic progression‑free survival for HRR‑mutated metastatic castration‑sensitive prostate cancer — a potential label expansion and commercial upside for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Atirmociclib Phase II success: a second‑line metastatic breast cancer study met its primary endpoint, strengthening Pfizer’s mid‑stage oncology pipeline and adding incremental clinical value that could support future partnerships or asset monetization. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst upgrades and bullish forecasts: recent analyst upgrades and an HSBC note highlighting strong upside have coincided with intraday buying and headline momentum, supporting the stock’s short‑term lift. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Positive Sentiment: Income/safety narrative: coverage framing Pfizer as a defensive, dividend‑paying option amid macro and oil volatility is attracting yield‑focused investors. That narrative helps support multiple expansion versus more cyclical sectors. Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.
• Neutral Sentiment: Pfizer vs Moderna sector comparison pieces highlight differing growth drivers (vaccines vs diversified pharma/oncology) but are more background for positioning than immediate stock movers. Pfizer vs Moderna: Which Pharma Stock Has More Upside?
• Neutral Sentiment: Early‑stage study updates: Pfizer advanced a PF‑07328948 liver study (Phase 1) while also closing one early melanoma program — incremental pipeline news that fine‑tunes expectations but doesn’t materially alter the company’s overall revenue base today. Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story
• Negative Sentiment: Program termination: Pfizer ended an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and highlights the usual R&D attrition risk that can temper optimism about pipeline breadth. Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not The Broader Pipeline

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on PFE shares. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays started coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. UBS Group assumed coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $28.14.

Pfizer Price Performance

PFE opened at $27.40 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market cap of $155.78 billion, a price-to-earnings ratio of 20.14 and a beta of 0.47. The stock has a fifty day simple moving average of $26.65 and a two-hundred day simple moving average of $25.59. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.